JD Health International Inc. (HKG:6618)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 143.65B |
| Revenue (ttm) | 81.73B |
| Net Income (ttm) | 5.98B |
| Shares Out | 3.21B |
| EPS (ttm) | 1.87 |
| PE Ratio | 23.93 |
| Forward PE | 18.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,820,924 |
| Average Volume | 6,976,147 |
| Open | 44.48 |
| Previous Close | 45.12 |
| Day's Range | 44.42 - 45.08 |
| 52-Week Range | 35.60 - 71.70 |
| Beta | 1.20 |
| RSI | 36.73 |
| Earnings Date | May 15, 2026 |
About JD Health International
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People’s Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical in... [Read more]
Financial Performance
In 2025, JD Health International's revenue was 73.44 billion, an increase of 26.28% compared to the previous year's 58.16 billion. Earnings were 5.38 billion, an increase of 29.16%.
Financial numbers in CNY Financial StatementsNews
JD Health International Earnings Call Transcript: H2 2025
Revenue grew 26.3% year-over-year to RMB 73.4 billion in 2025, with non-IFRS profit up 36.3% to RMB 6.5 billion and gross margin improving to 24.8%. Strategic AI investments, new drug launches, and omnichannel expansion drove growth, with significant market potential ahead.
JD Health International Earnings Call Transcript: H1 2025
Revenue grew 24.5% year-over-year to RMB 35.3 billion, with non-GAAP net profit up 35%. AI-driven services and omnichannel retail expansion fueled user growth to 200 million, while gross margin and operating efficiency improved.
JD Health International Earnings Call Transcript: H2 2024
Revenue grew 8.6% to RMB 58.16 billion in 2024, with net profit up 15.9% and active users surpassing 183 million. The company expanded its omnichannel and AI-driven healthcare services, expects double-digit revenue growth in 2025, and continues to lead in B2C pharmaceuticals.
JD Health International Earnings Call Transcript: H1 2024
Revenue grew 4.6% year-over-year to RMB 28.3 billion, with strong gains in core pharmaceuticals, service revenue, and user base. Gross margin and net profit reached record highs, driven by omni-channel expansion, digital innovation, and favorable policy support.
